{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:50:49Z","timestamp":1792795849439,"version":"4.5.0"},"publisher-location":"Chichester, UK","reference-count":33,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001447","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:16:04Z","timestamp":1069384564000},"source":"Crossref","is-referenced-by-count":100,"title":["Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)"],"prefix":"10.1002","author":[{"given":"RG","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JD","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DH","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,4,22]]},"reference":[{"key":"10.1002\/14651858.CD001447-BIB1|cit1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001447-BIB2|cit2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD001447-BIB3|cit3","unstructured":"Meininger V Lacomblez L Bensimon G Unpublished report: controlled trial of riluzole in patients with advanced ALS RP 54272-302 1995"},{"key":"10.1002\/14651858.CD001447-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"LaComblez","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001447-BIB5|cit5","first-page":"33","article-title":"Open label study of riluzole for the treatment of amyotrophic lateral sclerosis","volume":"8","author":"Arriada-Mendicoa","year":"1999","journal-title":"Revista Ecuatoriana de Neurologia"},{"key":"10.1002\/14651858.CD001447-BIB6|cit6","first-page":"357","article-title":"Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS","volume":"156","author":"Couratier","year":"2000","journal-title":"Revue Neurologique"},{"key":"10.1002\/14651858.CD001447-BIB7|cit7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-510X(99)00225-7","article-title":"The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation","volume":"31","author":"Desiato","year":"1999","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001447-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/00001756-199806010-00016","article-title":"Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy","volume":"9","author":"Kalra","year":"1998","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD001447-BIB9|cit9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-2007-1017633","article-title":"Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)","volume":"26","author":"Pongratz","year":"1999","journal-title":"Aktuelle Neurologie"},{"key":"10.1002\/14651858.CD001447-BIB10|cit10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archneur.55.4.526","article-title":"An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole","volume":"55","author":"Riviere","year":"1998","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001447-BIB11|cit11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)60977-4","article-title":"Effects of riluzole on symptom progression in amyotrophic lateral sclerosis","volume":"349","author":"Sojka","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001447-BIB12|cit12","first-page":"851","article-title":"Efficacy and safety of riluzole in patinets with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"key":"10.1002\/14651858.CD001447-BIB13|cit13","article-title":"Riluzole for motor neurone disease","volume-title":"Southampton: Wessex Institute for Health Research & Development (DEC Report 73)","author":"Booth-Clibborn","year":"1997"},{"issue":"Suppl","key":"10.1002\/14651858.CD001447-BIB14|cit14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","article-title":"El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases\/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \"Clinical limits of amyotrophic lateral sclerosis\" workshop contributors","volume":"124","author":"Brooks","year":"1994","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001447-BIB15|cit15","article-title":"The use of riluzole in the treatment of Amyotrophic Lateral Sclerosis (motor neurone disease). Working Group on Acute Purchasing","author":"Chilcott","year":"1997","journal-title":"Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield"},{"key":"10.1002\/14651858.CD001447-BIB16|cit16","unstructured":"Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR) Rilutek The European Agency for the Evaluation of Medicinal Products"},{"key":"10.1002\/14651858.CD001447-BIB17|cit17","article-title":"The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease","volume-title":"Health Technology Assessment - West Midlands Dev. & Assess. Svc","author":"Stewart","year":"2000"},{"key":"10.1002\/14651858.CD001447-BIB18|cit18","first-page":"185","article-title":"Riluzole and ALS therapy","volume":"146","author":"Hugon","year":"1996","journal-title":"Weiner Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD001447-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1212\/WNL.39.12.1635","article-title":"A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis","volume":"39","author":"Lacomblez","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447-BIB21|cit21","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/BF03160577","article-title":"The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS\/Riluzole Study Group III","volume":"244","author":"Meininger","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB22|cit22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/PL00007784","article-title":"What has changed with Riluzole?","volume":"247","author":"Meininger","year":"2000","journal-title":"Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1212\/WNL.47.4_Suppl_2.86S","article-title":"Clinical trials of riluzole in patients with amyotrophic lateral sclerosis","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1212\/WNL.52.7.1311","article-title":"Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)","volume":"52","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB25|cit25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/WNL.49.3.657","article-title":"Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole","volume":"49","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB26|cit26","unstructured":"National Institute for Clinical Excellence Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease Technology Appraisal Guidance 2001"},{"key":"10.1002\/14651858.CD001447-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001447-BIB28|cit28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-4388(96)80103-6","article-title":"Therapeutic horizons for amyotrophic lateral sclerosis","volume":"6","author":"Rothstein","year":"1996","journal-title":"Current Opinion in Neurobiology"},{"key":"10.1002\/14651858.CD001447-BIB29|cit29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJM199403033300911","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell?","volume":"330","author":"Rowland","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001447-BIB30|cit30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.50.1.66","article-title":"Prognostic indicators of survival in ALS","volume":"50","author":"Stambler","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447-BIB31|cit31","first-page":"43","article-title":"Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1999-2000)","volume":"2 Suppl 2","author":"Traynor","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"key":"10.1002\/14651858.CD001447-BIB32|cit32","first-page":"43","article-title":"The Kings' Database 1990-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis","volume":"2 Suppl 2","author":"Turner","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"key":"10.1002\/14651858.CD001447-BIB33|cit33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","article-title":"Riluzole","volume":"348","author":"Wokke","year":"1996","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:03:04Z","timestamp":1628542984000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001447"}},"subtitle":[],"editor":[{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2002,4,22]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001447","relation":{},"subject":[],"published":{"date-parts":[[2002,4,22]]}}}